AMGN Looks 6.9% Overvalued on GF Value™ as Dividend Sustainabili
HSBC downgraded Amgen (AMGN) from Buy to Hold, lowering the price target to $425. The company's dividend yield is 2.51% with a payout ratio of 44%, and a 3-year dividend growth rate of 7.1%. Amgen's GF Score is 86/100, reflecting strong profitability and growth. Insiders have sold $29.3M in shares, while the P/E ratio is 24.32x, near its 5-year median.
How this was made
The 30-second read
Why it matters
The downgrade highlights valuation concerns and may shift income‑focused investors toward alternatives.
Market read
Analyst downgrade of a mega‑cap biotech can influence sector sentiment and short‑term price action.
What to watch
Insider selling and high debt‑to‑equity could justify a more cautious stance despite the downgrade.
Background
Amgen is a leading biotech with a $211B market cap, solid dividend yield, and a GF Score of 86.
Ticker impact
HSBC analyst Morten Herholdt downgraded Amgen (AMGN) to Hold and cut the price target to $425.
Potential 2‑4% decline over the next few days as investors adjust expectations.
HSBC’s target cut reflects valuation concerns; no new product or earnings data accompany the change, so impact is modest.
Market effects
The downgrade may weigh on the broader biotech sector as peers are compared on valuation metrics.
U.S. market focus; limited regional spillover.
Minimal global effect beyond investors tracking large‑cap biotech names.
Counterpoint
Some investors may view the downgrade as an overreaction given Amgen’s strong dividend and pipeline.
Key entities
- companyAmgen Inc.
Biotech firm with dividend focus.
- analyst_firmHSBC
Issued the downgrade and new price target.
